Captopril and Olmesartan: Interaction Details
- Olmesartan
- Benicar
- Captopril
- Capoten
Medically reviewed by Dr. Brian Staiger, PharmD, BCPS
Also reviewed by the HelloPharmacist Editorial Team Updated AI-assisted Details about this page
- Dr. Brian Staiger, PharmD, BCPS, is a clinical pharmacist and pharmacotherapy specialist.
- AI-assisted, written
- AI is used only to summarize verified clinical information, never the open internet.
- Editorial policy
- How we build our interaction pages →
- Our AI policy →
A close look at the Captopril and Olmesartan interaction:
What Happens When You Take Captopril With Olmesartan
What can happen when they are taken together (rated Major)
Increased risk of adverse events (ie, , syncope, , changes in function, acute renal failure)
Interaction Deep Dive
A note from Dr. Brian Staiger If you’re a patient, this deep dive may be too technical, or bore you (or both). Read the plain-language explanation →
Combining an with an (ARB) to achieve dual blockade of the renin-angiotensin-aldosterone system has been linked to a higher rate of side effects. Among patients with established atherosclerotic disease, heart failure, or diabetes with end organ damage, giving an ACE inhibitor together with an ARB led to more frequent hypotension, syncope, hyperkalemia, and alterations in renal function (acute renal failure among them) than did either drug used on its own.4
A meta-analysis of patients with left ventricular dysfunction found that adding an ACE inhibitor to ARB therapy carried a greater overall risk of adverse events resulting in treatment discontinuation than ACE inhibitor therapy alone.1 As a rule, the two agents should not be used together; if their combined use cannot be avoided, blood pressure, renal function, and electrolytes should be monitored closely.3
The Captopril and Olmesartan Interaction, Explained
Both olmesartan (Benicar) and captopril (Capoten) lower blood pressure by working on the same body system, one that controls blood pressure, fluid, and potassium. Taking them together is like pressing the same brake twice. Studies show this combination can cause blood pressure that drops too low, dizziness or fainting, high potassium levels, and strain on the kidneys, sometimes serious.
Because of this, doctors usually avoid using these two together. If you have been prescribed both, please keep taking them as directed and talk with your pharmacist or doctor soon. Your care team can review your plan and, if both are truly needed, check your blood pressure, kidneys, and potassium closely to keep you safe.
Mechanism: dual RAAS blockade. Captopril () reduces angiotensin II formation; olmesartan () blocks AT1 receptors. No significant PK interaction is expected.
Effect: , with increased incidence of , syncope, , and function decline including acute renal failure versus either agent alone, notably in atherosclerotic disease, heart failure, or diabetes with end-organ damage. A meta-analysis in LV dysfunction showed more adverse-event discontinuations with ACEI plus ARB than with ACEI alone. Onset unspecified. Evidence: established.
Management:
- Generally avoid .
- If coadministration is necessary, closely monitor BP, serum creatinine/renal function, and electrolytes (especially potassium).
See the 4 references behind this explanation ↓
From the HelloPharmacist Pharmacy Team
AI-assisted: written with AI from this pair’s record in our interaction database, and reviewed by the HelloPharmacist pharmacy team. Written .
How we build these pages · How we use AI · Our editorial policy
Why Captopril and Olmesartan Interact
The likely mechanism
Dual blockade of the renin-angiotensin-aldosterone system
How to Manage the Captopril and Olmesartan Interaction
Because these two medicines work on the same system, care teams generally avoid using them together. Your prescriber may review whether both are needed or choose a different plan.
- If both are truly needed, your team may monitor you more closely, checking your blood pressure, kidney function, and electrolytes such as potassium.
- Keep taking your medicines as prescribed. Do not stop or change them on your own.
- Ask your pharmacist or prescriber whether this combination is right for you.
- Tell them about dizziness, fainting, or feeling lightheaded.
Management is individual — confirm any change with your pharmacist or prescriber.
Questions for Your Pharmacist
- Does my dose of Captopril or Olmesartan need adjusting while I take them together?
- What symptoms should prompt me to call you or my prescriber right away?
- Does the timing of my doses matter for this combination?
- Is there another option that avoids this interaction?
Literature Reports
1 report from the published literature. Each one is headed by the title of the published study it comes from.
What these reports are. Short summaries of published evidence on this combination: clinical studies, case reports and, at times, the FDA prescribing information for one of the drugs. They support this interaction, but it does not rest on them alone. It can also rest on prescribing information not summarized here, or on what is expected from how these two drugs, and others in their drug classes, are known to work.
-
Report 1 · Study title
Safety and tolerability of angiotensin-converting enzyme inhibitor versus the combination of angiotensin-converting enzyme inhibitor and angiotensin receptor blocker in patients with left ventricular dysfunction
In a systematic review and meta-analysis encompassing 18,160 patients with heart failure or left ventricular dysfunction drawn from 9 randomized trials, adding an (ARB) to therapy was linked to a higher risk of adverse events resulting in discontinuation of therapy when compared with ACE inhibitor therapy alone. Every patient had NYHA functional class II to IV heart failure, an ejection fraction of 45% or below, or left ventricular dysfunction in the acute postmyocardial infarction setting.
The agents included were losartan, candesartan, valsartan, irbesartan, and telmisartan. Duration of follow-up ranged from 4 weeks to 41 months.
The analysis showed that combination therapy raised the risk of developing any adverse effect by 2.3%. The risk of rose by 1.1%, the risk of worsening function rose by 1%, and the risk of rose by 0.6%.
In contrast, the risk of angioedema or cough was not significantly different between the treatment arms. When a combination strategy is warranted, patients should undergo close monitoring for potential adverse effects.1
Captopril and Olmesartan: Common Questions
How serious is the Captopril and Olmesartan interaction?
It is rated major. Potentially serious — often needs a change or close monitoring.
How is the Captopril and Olmesartan interaction managed?
Because these two medicines work on the same system, care teams generally avoid using them together. Your prescriber may review whether both are needed or choose a different plan. If both are truly needed, your team may monitor you more closely, checking your blood pressure, kidney function, and electrolytes such as potassium. Keep taking your medicines as prescribed. Do not stop or change them on… Management is individual — always follow your own care team's guidance.
Who is at higher risk from the Captopril and Olmesartan interaction?
The interaction record names this group as more likely to be affected:
- People with kidney problems
If this describes you, tell your pharmacist or prescriber.
How quickly could this interaction happen?
The documented onset is "unspecified". The timing of this interaction is not well characterized.
How strong is the evidence for this interaction?
The evidence is graded "established". Well documented — supported by controlled studies or strong clinical data.
Ask About the Captopril and Olmesartan Interaction
Ask in your own words about taking Captopril and Olmesartan together. The answer comes from this page’s interaction record and both drugs’ own information.
This box answers questions about this one combination only. For anything else about either drug, open its drug information page or ask a pharmacist.
AI answers from this page’s record and both drugs’ information, never the open internet. AI can make mistakes, so always check with your doctor or pharmacist.
References (4)
- Lakhdar R, Al-Mallah MH, & Lanfear DE: Safety and tolerability of angiotensin-converting enzyme inhibitor versus the combination of angiotensin-converting enzyme inhibitor and angiotensin receptor blocker in patients with left ventricular dysfunction. J Card Fail 2008; 14(3):181-188.
- Product Information: Lotensin(R) oral tablets, benazepril HCl oral tablets. Validus Pharmaceuticals LLC (per FDA), Parsippany, NJ, 2014. DailyMed
- Product Information: EXFORGE oral tablets, amlodipine valsartan oral tablets. Novartis Pharmaceuticals Corporation (per FDA), East Hanover, NJ, 2019. DailyMed
- Product Information: COZAAR(R) oral tablets, losartan potassium oral tablets. Merck Sharp & Dohme Corp. (per FDA), Whitehouse Station, NJ, 2011. DailyMed
Other Serious Interactions of Captopril and Olmesartan
Also serious with Olmesartan
Also serious with Captopril
These Medications Also Interact With Supplements
Prescription drugs aren't the whole picture — herbal and dietary supplements can interact with them too. From the evidence-graded Natural Medicines database:
With Captopril
- Activated CharcoalMajor
- American HelleboreMajor
- American MistletoeMajor
- AsarabaccaMajor
- Siberian CockleburMajor
- TyramineMajor
- Vitamin B6Moderate
- SodiumModerate
- + 158 more
Check everything you take with our drug–supplement interaction checker.
Still Have Questions About This Combination?
Every question gets a real answer from a licensed pharmacist — free, as soon as they can.
About This Library
Built in-house, documented one interaction at a time. Our interaction database is not a complete list of every known interaction: a combination that isn't listed here hasn't been documented by us yet, which never means it's safe. Checking everything you take at once? Ask your pharmacist to review your full medication list. How we build and review it →
What Each Rating Means
Severity Levels
- Contraindicated These should generally not be used together.
- Major Potentially serious — often needs a change or close monitoring. This interaction.
- Moderate Can be significant — usually manageable with monitoring.
- Minor Usually limited clinical impact.
Evidence Grades
- EstablishedWell documented — supported by controlled studies or strong clinical data. This interaction.
- ProbableGood supporting evidence, though not definitively proven.
- SuspectedSome evidence suggests this interaction, but it is not well established.
- PossibleLimited or conflicting evidence; the interaction may occur.
- TheoreticalExpected from how the drugs work, or from studies of similar drugs; this exact pair has little direct study.
How Soon It Shows
- RapidEffects can appear quickly, often within about 24 hours of combining the drugs.
- DelayedEffects tend to build up gradually over days to weeks.
- UnspecifiedThe timing of this interaction is not well characterized. This interaction.
Ratings come from the documented interaction literature and are reviewed by a pharmacist. They describe the documented risk of the combination, not what will necessarily happen to you — your dose, timing, and health picture all matter.